Cargando…

Efficacy and Biomarker Exploration of Sintilimab Combined With Chemotherapy in the Treatment of Advanced Penile Squamous Cell Carcinoma—A Report of Two Cases

Penile squamous cell carcinoma is a rare malignant tumor of the male reproductive system. We report two cases of advanced penile squamous cell carcinoma with persistent partial response/complete response after sintilimab combined with chemotherapy and analyze the relevant tumor biomarkers.

Detalles Bibliográficos
Autores principales:	Mei, Xinkuan, Zhao, Yanyan, Zhang, Yiruo, Liao, Jinhua, Jiang, Chen, Qian, Hesheng, Du, Yingying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021724/ https://www.ncbi.nlm.nih.gov/pubmed/35463336 http://dx.doi.org/10.3389/fonc.2022.823459

Ejemplares similares

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Lv, Huilai, et al.
Publicado: (2022)

Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma
por: You, Maojin, et al.
Publicado: (2022)

Efficacy and safety of anti-programmed cell death protein 1 antibody combination therapy in patients with advanced experienced epidermal growth factor receptor-tyrosine kinase inhibitor-resistant lung adenocarcinoma: a retrospective cohort study
por: Wan, Chang, et al.
Publicado: (2023)

Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma
por: Shao, Taihang, et al.
Publicado: (2022)

Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR‐mutated non‐small cell lung cancer patient: A case report
por: Zhang, Yiruo, et al.
Publicado: (2020)

Efficacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China
por: Yang, Wenyu, et al.
Publicado: (2023)

Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events
por: Tu, Lingfang, et al.
Publicado: (2021)

Sintilimab Combined with Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma in Second-Line Setting—A Multi-Center Observational Study
por: Ding, Xiaoyan, et al.
Publicado: (2022)

Case Report: sintilimab-induced Stevens-Johnson Syndrome in a patient with advanced lung adenocarcinoma
por: Li, Xueqin, et al.
Publicado: (2023)

Regorafenib combined with sintilimab as second-line treatment for advanced HCC patient: a case report
por: Wan, Yanzhi, et al.
Publicado: (2023)

The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
por: Lv, Huilai, et al.
Publicado: (2023)

Case report: Undifferentiated sarcoma with multiple tumors involved in Lynch syndrome: Unexpected favorable outcome to sintilimab combined with chemotherapy
por: Liu, Jiaying, et al.
Publicado: (2022)

Immunotherapy Combined With Chemotherapy for Postoperative Recurrent Penile Squamous Cell Carcinoma: A Case Report and Literature Review
por: Li, Na, et al.
Publicado: (2022)

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
por: Chen, Pingyu, et al.
Publicado: (2022)

Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review
por: Liu, Zichang, et al.
Publicado: (2023)

Sintilimab: A Promising Anti-Tumor PD-1 Antibody
por: Zhang, Lin, et al.
Publicado: (2020)

Case report: A rare case of sintilimab-induced gastric stenosis and literature review
por: Song, Kunkun, et al.
Publicado: (2023)

Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study
por: Wang, Lijun, et al.
Publicado: (2023)

Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment
por: Dai, Gangyi, et al.
Publicado: (2023)

Case Report: Two Cases of Chemotherapy Refractory Metastatic Penile Squamous Cell Carcinoma With Extreme Durable Response to Pembrolizumab
por: Chahoud, Jad, et al.
Publicado: (2020)

The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma
por: Zhao, Zheng, et al.
Publicado: (2023)

Clinical Study of Sintilimab as Second-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Retrospective Study
por: Nie, Caiyun, et al.
Publicado: (2021)

Warthy-Basaloid Squamous Cell Carcinoma of Penile – Case Report
por: Domian, Natalia, et al.
Publicado: (2021)

The Biomarker Potential of Caveolin-1 in Penile Cancer
por: Panic, Andrej, et al.
Publicado: (2021)

Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study
por: Jiang, Haiping, et al.
Publicado: (2020)

First-line sintilimab plus chemotherapy in locally advanced or metastatic esophageal squamous cell carcinoma: A cost-effectiveness analysis from China
por: Shen, Jian, et al.
Publicado: (2022)

Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer
por: Ma, Baozhen, et al.
Publicado: (2022)

Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma
por: Liu, Lulu, et al.
Publicado: (2023)

Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review
por: Yan, Zheng, et al.
Publicado: (2020)

Penile squamous cell carcinoma originating from a silicone granuloma
por: Chen, Yi-Hsuan, et al.
Publicado: (2023)

Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study
por: Chen, Xiaofeng, et al.
Publicado: (2022)

The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
por: Wang, Jianzheng, et al.
Publicado: (2022)

Case Report: Toxic epidermal necrolysis associated with sintilimab in a patient with relapsed thymic carcinoma
por: Yang, Huayu, et al.
Publicado: (2022)

Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer
por: Wang, Ting, et al.
Publicado: (2023)

A Case Report of Refractory Penile Squamous Cell Carcinoma Treated With Surgical Resection, Chemotherapy and External Beam Radiation Therapy
por: Zong, Perry, et al.
Publicado: (2023)

Neoadjuvant chemotherapy and penile conservation in the management of Buschke – Lowenstein tumor, a case report
por: El Khoury, Anthony, et al.
Publicado: (2019)

The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Cao, Fei, et al.
Publicado: (2021)

Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)
por: Xu, Jianming, et al.
Publicado: (2022)

Intraarterial chemotherapy with gemcitabine and cisplatin in locally advanced or recurrent penile squamous cell carcinoma
por: Liu, Jian-Ye, et al.
Publicado: (2013)

Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial
por: Zhang, Zhi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v2l3ng5a00n0pobp523i06emj2